Sandoz has announced that it will sponsor the hydroxychloroquine to be used for a US Phase III clinical trial in approximately 440 coronavirus patients. According to the agreement with the US Food and Drug Administration, the company will provide the doses for the trial “to address the need for science-based investigation following early pre-clinical and clinical evidence that hydroxychloroquine may help hospitalized patients with COVID-19 disease.”
Sandoz, Mylan And Teva Take Bigger Steps To Tackle COVID-19
Sandoz Sponsors Hydroxychloroquine For Large Clinical Trial
Sandoz is sponsoring a major hydroxychloroquine trial while other major industry players like Teva, Mylan, Apotex, Stada and Lupin are also accelerating efforts to fight the coronavirus crisis. Accord and Wavelength Pharma have stepped up their manufacturing to meet demand, as the AAM has cancelled its annual meeting.
More from Generics
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.